Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.8, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SHY | ZBH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $83.18 | $107.71 |
52-Week Low | $81.79 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY trades at $81.96, showing minimal daily movement with a slight decline of 0.04%. The technical outlook is mixed with a bullish overall signal but bearish moving averages, while key support and resistance cluster around $82. Recent corporate actions include consistent dividend payments of $0.24, with the latest scheduled for July 2026. Financial ratios are not disclosed in the provided data, limiting fundamental visibility.
The outlook for SHY is clouded by incomplete financial data, though steady dividends provide income appeal. Key risks include interest rate sensitivity amid Federal Reserve uncertainty, as bond market volatility could impact performance. Investors should seek updated SEC filings for fundamental clarity before considering positions.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
